4.6 Review

Lessons Learned: Transfer of the High-Definition Circulating Tumor Cell Assay Platform to Development as a Commercialized Clinical Assay Platform

Journal

CLINICAL PHARMACOLOGY & THERAPEUTICS
Volume 102, Issue 5, Pages 777-785

Publisher

WILEY
DOI: 10.1002/cpt.645

Keywords

-

Funding

  1. National Cancer Institute of the National Institutes of Health (NIH) [U54 CA143906]

Ask authors/readers for more resources

Planning and transfer of a new technology platform developed in an academic setting to a start-up company for medical diagnostic product development may appear daunting and costly in terms of complexity, time, and resources. In this review we outline the key steps taken and lessons learned when a technology platform developed in an academic setting was transferred to a start-up company for medical diagnostic product development in the interest of elucidating development toolkits for academic groups and small start-up companies starting on the path to commercialization and regulatory approval.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available